drugset / Trial / NCT06134414

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06134414

Phase 2 Not yet recruiting 40 enrolled Wuhan Createrna Science and Technology Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.

Timeline

Start
2025-12
Primary completion
2027-07
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MY008211A Unknown 400 mg Oral
Subject MY008211A Unknown 600 mg Oral